Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–3 of 3 results
Advanced filters: Author: Eugen Dhimolea Clear advanced filters

  • Fully human monoclonal antibodies (mAbs), which have the potential to be less immunogenic than earlier humanized and chimeric mAbs, are the most rapidly growing class of mAbs in clinical development. Here, Reichert and colleagues highlight trends in the development of human mAbs, seven of which have so far gained regulatory approval.

    • Aaron L. Nelson
    • Eugen Dhimolea
    • Janice M. Reichert
    Reviews
    Nature Reviews Drug Discovery
    Volume: 9, P: 767-774

  • The use of natural killer (NK) cells in immunotherapy as an alternative to allogeneic T cells is gaining ground. Here, two genome-scale high-throughput platforms are used to identify genes that modulate the sensitivity of multiple solid tumor cell lines to NK-mediated killing.

    • Michal Sheffer
    • Emily Lowry
    • Constantine S. Mitsiades
    Research
    Nature Genetics
    Volume: 53, P: 1196-1206